Navigation Links
Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd.
Date:11/4/2011

SHENZHEN, China, Nov. 4, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ("Global Pharm" or the "Company"), a China-based, growing vertically integrated pharmaceutical company engaged in pharmaceutical-related products distribution, Traditional Chinese Medicine ("TCM") herbs cultivation and processing business through its subsidiaries in Anhui, Jilin, Guangdong and Shandong provinces, today announced that, on October 31, 2011, it completed the acquisition of the 100% equity interest of Qingdao Likang Pharmaceutical Co., Ltd ("Qingdao Likang"), a city-level pharmaceutical distributor located in Qingdao, Shandong Province. With the completion of this acquisition, Qingdao Likang becomes an indirect wholly owned subsidiary of the Company.

"We are pleased to announce the completion of this acquisition, which brings us to a total of six companies acquired this year. Following the earlier acquisitions of three city-level pharmaceutical distributors in Shandong Province, this addition further extends our distribution coverage into the city of Qingdao and provides us with critical access to Shandong Peninsula, one of the most economically developed regions in China with a relatively higher level of consumption for pharmaceutical products," stated Mr. Yun-lu Yin, Chief Executive Officer of Global Pharm. "For the rest of 2011, we will focus on integrating these newly acquired businesses into our current operations. Through our efforts, we believe that we will be able to broaden our regional market coverage, expand our customer base, diversify our product portfolios and enhance and maintain our position in the Shandong pharmaceutical market."

Qingdao Likang distributes approximately 4,000 types of pharmaceutical-related products mainly to hospitals, community clinics, and drugstores. It owns a modern warehouse of approximately 1,100 square meters (approximately 11,840 square feet), which has been certified under the Good Supply Practice ("GSP") quality standards in the PRC. Under these standards, wholesale and retail enterprises in China must implement strict control on the distribution of pharmaceutical products with respect to, among other things, staff qualifications, distribution premises, warehouse, inspection equipment and facilities, management and quality control in order to obtain a GSP certificate to carry out business in China.

Under the terms of this transaction, the Company is required to pay approximately US$1.6 million in cash to the former shareholders of Qingdao Likang.

About Qingdao LikangQingdao Likang, established on July 7, 1998, is a city-level pharmaceutical distributor in Qingdao city, Shandong province. It occupies approximately 1,500 square meters (approximately 16,146 square feet) of GSP-certified warehouse and offices, and distributes more than 4,000 types of pharmaceutical-related products, mainly including injections, tablets, pastes, granules, capsules and medical instruments.

About Global PharmGlobal Pharm Holdings Group, Inc., a growing integrated pharmaceutical company, is engaged in the pharmaceutical distribution, Traditional Chinese Medicine (TCM) herb cultivation and herbal pieces processing business in China. The Company focuses on building regional distribution channels, as well as local capillary sales network with high-margin products portfolio. Currently, its sales network covers Shandong, Jilin, Anhui and Guangdong provinces. Global Pharm seeks to establish an integrated value chain in the pharmaceutical industry through strategic acquisitions within TCM production, pharmaceutical distribution and the retail sectors. For further information, please visit the Company's corporate website at http://www.globalpharmholdings.com.

Forward-looking StatementsCertain statements set forth in this press release contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. Such statements reflect the current view of our management with respect to future events and are subject to risks, uncertainties, assumptions and other factors as they relate to our industry, our operations and results of operations, plans for future facilities, capital-expenditure plans and any businesses that we may acquire. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the U.S. federal securities laws, we do not intend to update any of the forward-looking statements to conform them to actual results.For Additional Information ContactGlobal Pharm Holdings Group, Inc.Ms. Susan LiuPhone: +86-755-3693-9373 Email: susanliu@globalpharmholdings.com
'/>"/>

SOURCE Global Pharm Holdings Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Top 10 Medical Devices Market (2010 - 2015)
2. Global Trend in Diabetes Could Exact Catastrophic Toll on Emerging Global Healthcare Systems
3. The Global Market for Diabetes Drugs and Devices is Booming: Expected to Attain a Market Size of USD 114.3 Billion by 2016
4. Sanofi Tops Pfizer as Number One for Global Pharma Sales
5. Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey
6. Philips Enters North American Mammography Market, Underscoring its Global Commitment to Womens Health Care
7. Global Strategic Marketing Key to Success in Oncology Launches in the Pharmaceutical Sector
8. Hypertronics Partners with UBM Canon, the Leading Global Medical Device Industry Source, to Co-Host Strategies for Avoiding Device Failure Seminar
9. Global Pharm Announces the Closing of US$15 Million Redeemable Convertible Bonds Financing
10. Global Eyeglasses Industry
11. S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):